Carcinoma in situ (CIS) of the bladder is an aggressive form of high-grade NMIBC.
UGN-201 (imiquimod) is an investigational local immunotherapy for the treatment of CIS.
UGN-201 is a proprietary formulation of imiquimod, a toll-like receptor 7/8 (TLR7/8 agonist) designed to elicit an immune response to bladder cancer. A Phase 1b study suggested a preliminary efficacy signal in patients with CIS. UGN-201 previously received Orphan Drug Designation for CIS.
We continue to advance research for UGN-201 as a single agent and in combination with the new checkpoint inhibitors for the treatment of high-grade urothelial cancer.
499 Park Avenue, Suite 1200
NY 10022, U.S.A
+1-646-768-9780 ext 1001